Last reviewed · How we verify
Rabeprazloe+bismuth+amoxicillin+clarithromycin
This quadruple therapy combination eradicates Helicobacter pylori by suppressing gastric acid, disrupting bacterial cell walls, and inhibiting protein synthesis.
This quadruple therapy combination eradicates Helicobacter pylori by suppressing gastric acid, disrupting bacterial cell walls, and inhibiting protein synthesis. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | Rabeprazloe+bismuth+amoxicillin+clarithromycin |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Proton pump inhibitor + bismuth salt + beta-lactam antibiotic + macrolide antibiotic combination |
| Target | H+ ATPase (rabeprazole); H. pylori urease and cell wall (bismuth); bacterial peptidoglycan (amoxicillin); bacterial ribosome (clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an inhospitable environment for H. pylori. Bismuth acts as a bactericidal agent that damages the bacterial cell wall and inhibits urease enzyme. Amoxicillin and clarithromycin are antibiotics that inhibit bacterial protein synthesis and cell wall formation, working synergistically to eliminate the pathogen.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
- Allergic reactions (amoxicillin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: